<SEC-DOCUMENT>0000935836-25-000529.txt : 20250814
<SEC-HEADER>0000935836-25-000529.hdr.sgml : 20250814
<ACCEPTANCE-DATETIME>20250814150840
ACCESSION NUMBER:		0000935836-25-000529
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250814
DATE AS OF CHANGE:		20250814

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TELA Bio, Inc.
		CENTRAL INDEX KEY:			0001561921
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				455320061
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-91207
		FILM NUMBER:		251217894

	BUSINESS ADDRESS:	
		STREET 1:		1 GREAT VALLEY PARKWAY, SUITE 24
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355
		BUSINESS PHONE:		484-320-2930

	MAIL ADDRESS:	
		STREET 1:		1 GREAT VALLEY PARKWAY, SUITE 24
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LYTTON LAURENCE W
		CENTRAL INDEX KEY:			0001105806
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	MAIL ADDRESS:	
		STREET 1:		467 CENTRAL PARK WEST
		CITY:			NY
		STATE:			NY
		ZIP:			10025
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0000935836-24-000692</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: LYTTON LAURENCE W -->
          <cik>0001105806</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>2</amendmentNo>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>06/30/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001561921</issuerCik>
        <issuerName>TELA Bio, Inc.</issuerName>
        <issuerCusip>872381108</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>1 GREAT VALLEY PARKWAY, SUITE 24</com:street1>
          <com:city>MALVERN</com:city>
          <com:stateOrCountry>PA</com:stateOrCountry>
          <com:zipCode>19355</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Lytton, Laurence W.</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>3424191.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>3424191.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3424191.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>8.5</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>The shares of Common Stock beneficially owned by the reporting person consist of 2,724,191 shares of Common Stock and 700,000 shares of Common Stock issuable pursuant to outstanding warrants.  The percentages reported in this Schedule 13G are based on 39,616,440 shares of Common Stock outstanding as of August 4, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>TELA Bio, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>1 Great Valley Parkway, Suite 24, Malvern, PA 19355</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Laurence W. Lytton</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>467 Central Park West
New York, NY 10025</principalBusinessOfficeOrResidenceAddress>
        <citizenship>United States</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>3,424,191</amountBeneficiallyOwned>
        <classPercent>8.5%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>3,424,191</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>3,424,191</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Lytton, Laurence W.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Laurence W. Lytton</signature>
        <title>Reporting Person</title>
        <date>08/14/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
